Despite the low HER2 score, a median PFS of 11 months was observed, and 40.0% of patients (26/65) in this subgroup in J101 responded to T-DXd treatment (Fig. 3A shows the waterfall plot of tumor shrinkage as related to QCS-membrane OD and IHC status). Here, ERBB2 is linked to neoplasm.